Sildenafil for Treatment of Choroidal Ischemia
September 24, 2022
ClinicalTrials.gov Identifier: NCT04356716
The hypothesis of this study is to determine if there is a benefit afforded by the use of systemic Sildenafil to patients with choroidal and retinal degenerations and dystrophies, such as vitelliform degeneration, dry and reticular age-related macular degeneration (AMD) as well as patients with hereditary and acquired retinal dystrophies such as retinitis pigmentosa and central serous retinopathy.
Sponsor: Columbia University Medical Center in NY
Name: Suzanne Daly, RN, BSN
Note: The status of this study is listed as recruiting, but it also says results are expected in December 2022.